These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16682711)

  • 1. Low-molecular-weight heparins as adjunctive therapy to thrombolytics: extracting the best data.
    Bailey AL; Steinhubl SR
    CMAJ; 2006 May; 174(10):1431-2. PubMed ID: 16682711
    [No Abstract]   [Full Text] [Related]  

  • 2. Subcutaneous enoxaparin following thrombolysis and intravenous unfractionated heparin in ST-elevation acute myocardial infarction: safety and efficacy of low vs full dose.
    Rubboli A; Gatti C; Spinolo L; Parollo R; Spitali G; Maresta A
    Minerva Cardioangiol; 2006 Feb; 54(1):131-7. PubMed ID: 16467747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data.
    Armstrong PW; Chang WC; Wallentin L; Goldstein P; Granger CB; Bogaerts K; Danays T; Van de Werf F;
    CMAJ; 2006 May; 174(10):1421-6. PubMed ID: 16682709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction.
    Wallentin L; Goldstein P; Armstrong PW; Granger CB; Adgey AA; Arntz HR; Bogaerts K; Danays T; Lindahl B; Mäkijärvi M; Verheugt F; Van de Werf F
    Circulation; 2003 Jul; 108(2):135-42. PubMed ID: 12847070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial.
    Antman EM; Louwerenburg HW; Baars HF; Wesdorp JC; Hamer B; Bassand JP; Bigonzi F; Pisapia G; Gibson CM; Heidbuchel H; Braunwald E; Van de Werf F
    Circulation; 2002 Apr; 105(14):1642-9. PubMed ID: 11940541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II).
    Ross AM; Molhoek P; Lundergan C; Knudtson M; Draoui Y; Regalado L; Le Louer V; Bigonzi F; Schwartz W; de Jong E; Coyne K;
    Circulation; 2001 Aug; 104(6):648-52. PubMed ID: 11489769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Tenecteplase--the best among the equals.".
    Saran RK; Sethi R; Nagori M
    Indian Heart J; 2009; 61(5):454-8. PubMed ID: 20635761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction.
    Sinnaeve PR; Alexander JH; Bogaerts K; Belmans A; Wallentin L; Armstrong P; Adgey JA; Tendera M; Diaz R; Soares-Piegas L; Vahanian A; Granger CB; Van De Werf FJ
    Am Heart J; 2004 Jun; 147(6):993-8. PubMed ID: 15199346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
    Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators
    Lancet; 2001 Aug; 358(9282):605-13. PubMed ID: 11530146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular-weight heparins in acute myocardial infarction: rationale and results of a pilot study.
    Ross AM; Coyne K; Hammond M; Lundergan CF
    Clin Cardiol; 2000 Jul; 23(7):483-5. PubMed ID: 10894434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tenecteplase in Indian patients with ST-segment elevation myocardial infraction: a future perspetive.
    Tewari S
    Indian Heart J; 2008; 60(6):504-6. PubMed ID: 19276486
    [No Abstract]   [Full Text] [Related]  

  • 13. ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction.
    Armstrong PW; Wagner G; Goodman SG; Van de Werf F; Granger C; Wallentin L; Fu Y;
    Eur Heart J; 2003 Aug; 24(16):1515-22. PubMed ID: 12919776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenecteplase: new preparation. Another thrombolytic agent for myocardial infarction: a slightly simpler treatment.
    Prescrire Int; 2002 Jun; 11(59):83-4. PubMed ID: 12068843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction.
    Melandri G; Vagnarelli F; Calabrese D; Semprini F; Nanni S; Branzi A
    Vasc Health Risk Manag; 2009; 5(1):249-56. PubMed ID: 19436656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variations in pre-hospital fibrinolysis process of care: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic 3 Plus international acute myocardial infarction pre-hospital care survey.
    Welsh RC; Goldstein P; Adgey J; Verheugt F; Bestilny SA; Wallentin L; Van de Werf F; Armstrong PW;
    Eur J Emerg Med; 2004 Jun; 11(3):134-40. PubMed ID: 15167171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet and antithrombin therapy.
    Fernández-Ortiz A; Jang IK; Fuster V
    Coron Artery Dis; 1994 Apr; 5(4):297-305. PubMed ID: 8044341
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of tenecteplase in ST elevation myocardial infarction patients from the Elaxim Indian Registry.
    Iyengar SS; Nair T; Sathyamurthy I; Hiremath JS; Jadhav U; Kumbla D; Jain RK; Srinivasan M; Sahoo PK; Chawla K; Katiyal VK
    Indian Heart J; 2009; 61(5):480-1. PubMed ID: 20635768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombolysis: newer thrombolytic agents and their role in clinical medicine.
    Nordt TK; Bode C
    Heart; 2003 Nov; 89(11):1358-62. PubMed ID: 14594904
    [No Abstract]   [Full Text] [Related]  

  • 20. The place of tenecteplase in management of STEMI.
    Chopra HK
    Indian Heart J; 2009; 61(5):408-9. PubMed ID: 20635752
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.